Talphera (NASDAQ:TLPH) Shares Down 0.3% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH)’s share price fell 0.3% on Thursday . The company traded as low as $0.7808 and last traded at $0.8079. 39,878 shares traded hands during trading, a decline of 77% from the average session volume of 173,561 shares. The stock had previously closed at $0.81.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TLPH shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Talphera to a “hold” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Talphera currently has a consensus rating of “Hold” and an average price target of $6.00.

Talphera Price Performance

The business has a fifty day moving average price of $1.01 and a two-hundred day moving average price of $0.98. The firm has a market cap of $37.66 million, a PE ratio of -2.13 and a beta of 0.46.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC lifted its position in Talphera by 4.6% in the 4th quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company’s stock worth $5,314,000 after buying an additional 206,957 shares in the last quarter. Rosalind Advisors Inc. raised its holdings in shares of Talphera by 118.9% during the third quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after acquiring an additional 2,381,818 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock valued at $3,120,000 after purchasing an additional 1,500,000 shares during the last quarter. Empery Asset Management LP acquired a new stake in Talphera during the fourth quarter valued at $1,520,000. Finally, Cantor Fitzgerald L. P. purchased a new position in Talphera in the fourth quarter valued at about $658,000. 37.67% of the stock is owned by hedge funds and other institutional investors.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.